Oncology News & Perspectives

Featured Exclusive

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richardson, MD, who served as t...

Top Oncology Stories

Friday, March 27, 2020
The American Society of Breast Surgeons has released an executive summary of recommendations for prioritizing, treating, and triaging patients with breast cancer during the COVI...
Thursday, March 26, 2020
Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults wit...
Wednesday, March 25, 2020
Patients with cancer are at increased risk of infection with severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, according to a medical records...
Tuesday, March 24, 2020
Colorectal cancer is the third leading cause of cancer death and the fourth most common diagnosed cancer in the world. Often, this disease is left undiagnosed until it reach...
Monday, March 23, 2020
According to the results of a recently published study, carcinogenic biomarkers strongly linked to bladder cancer risk are found in the urine samples of electronic cigarette...

Expert Perspectives

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two ...
Colorectal cancer is the third leading cause of cancer death and the fourth most common diagnosed cancer in the world. Often, this disease is left undiagnosed until it reaches an advanced stage. Unfortunately, late-stage me...
Results of TRIBE2, a phase 3 trial (NCT02339116), show that the triplet treatment FOLFOXIRI (fluorouracil/leucovorin/oxaliplatin/irinotecan) plus bevacizumab is more effective at treating patients with metastatic colorectal...
Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a mortality rate of over 50% for locally advanced disease. However, few clinical trials have been conducted due to its low incidence rate. Nephrouretere...
​United States Dietary Guidelines recommend that adults and children aged 9 or older consume three cups per day of low-fat or fat-free milk and dairy foods, or alternatively, three cups of calcium-fortified soymilk. However, a...

Original Research

Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline kn...
At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats i...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has reveale...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...

Copyright © 2020 i3 Health. All rights reserved.